{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:35:08Z","timestamp":1785425708428,"version":"3.56.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00277-023-05100-0","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T08:02:58Z","timestamp":1673856178000},"page":"385-392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse\/refractory Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7817-1665","authenticated-orcid":false,"given":"Francesco","family":"Gaudio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Loseto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bozzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Potito Rosario","family":"Scalzulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Mazzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Tonialini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Fesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Masciopinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Arcuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Clemente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Scardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Tarantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorella","family":"Melillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Pavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Michele","family":"Carella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Di Renzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Guarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"key":"5100_CR1","doi-asserted-by":"publisher","unstructured":"Gaudio F, Giordano A, Pavone V, Perrone T, Curci P, Pastore D, Delia M, De' Risi C, Spina A, Liso V, Specchia G (2011) Outcome of very late relapse in patients with Hodgkin's Lymphomas. Adv Hematol 2011:707542. https:\/\/doi.org\/10.1155\/2011\/707542","DOI":"10.1155\/2011\/707542"},{"issue":"8","key":"5100_CR2","doi-asserted-by":"publisher","first-page":"e506","DOI":"10.1016\/j.clml.2020.03.006","volume":"20","author":"FE Laddaga","year":"2020","unstructured":"Laddaga FE, Moschetta M, Perrone T, Perrini S, Colonna P, Ingravallo G, D\u2019abbicco D, Specchia G, Gaudio F (2020) Long-term Hodgkin Lymphoma survivors: a glimpse of what happens 10 years after treatment. Clin Lymphoma Myeloma Leuk 20(8):e506\u2013e512. https:\/\/doi.org\/10.1016\/j.clml.2020.03.006","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"5100_CR3","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.3390\/jcm9051384","volume":"9","author":"E Domingo-Dom\u00e8nech","year":"2020","unstructured":"Domingo-Dom\u00e8nech E, Sureda A (2020) Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation. J Clin Med 9(5):1384. https:\/\/doi.org\/10.3390\/jcm9051384","journal-title":"J Clin Med"},{"issue":"10","key":"5100_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12102887","volume":"12","author":"TJ Voorhees","year":"2020","unstructured":"Voorhees TJ, Beaven AW (2020) Therapeutic updates for relapsed and refractory classical hodgkin lymphoma. Cancers (Basel) 12(10):1\u201316. https:\/\/doi.org\/10.3390\/cancers12102887","journal-title":"Cancers (Basel)"},{"key":"5100_CR5","doi-asserted-by":"publisher","unstructured":"di Renzo N, Gaudio F, Stella CC et al (2020) Relapsing\/refractory hl after autotransplantation: which treatment? Acta Biomedica 91(S-5). https:\/\/doi.org\/10.23750\/abm.v91iS-5.9912","DOI":"10.23750\/abm.v91iS-5.9912"},{"issue":"1","key":"5100_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.clml.2018.08.012","volume":"19","author":"F Gaudio","year":"2019","unstructured":"Gaudio F, Mazza P, Carella AM, Mele A, Palazzo G, Pisapia G, Carluccio P, Pastore D, Cascavilla N, Specchia G, Pavone V (2019) Outcomes of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for Hodgkin Lymphomas: a retrospective multicenter experience by the Rete Ematologica Pugliese (REP). Clin Lymphoma Myeloma Leuk 19(1):35\u201340. https:\/\/doi.org\/10.1016\/j.clml.2018.08.012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"5100_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12102887","volume":"12","author":"TJ Voorhees","year":"2020","unstructured":"Voorhees TJ, Beaven AW (2020) Therapeutic updates for relapsed and refractory classical hodgkin lymphoma. Cancers (Basel) 12(10):1\u201316. https:\/\/doi.org\/10.3390\/cancers12102887","journal-title":"Cancers (Basel)"},{"key":"5100_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26500","author":"H Yhim","year":"2022","unstructured":"Yhim H, Eshet Y, Metser U et al (2022) Risk stratification for relapsed\/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.26500","journal-title":"Am J Hematol"},{"key":"5100_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03662-6","author":"F Gaudio","year":"2019","unstructured":"Gaudio F, Mazza P, Mele A et al (2019) Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin\u2019s lymphoma patients. Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-019-03662-6","journal-title":"Ann Hematol"},{"issue":"12","key":"5100_CR10","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"R Chen","year":"2016","unstructured":"Chen R, Gopal AK, Smith SE et al (2016) Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128(12):1562\u20131566. https:\/\/doi.org\/10.1182\/blood-2016-02-699850","journal-title":"Blood"},{"issue":"18","key":"5100_CR11","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase ii study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol 30(18):2183\u20132189. https:\/\/doi.org\/10.1200\/JCO.2011.38.0410","journal-title":"J Clin Oncol"},{"key":"5100_CR12","doi-asserted-by":"publisher","unstructured":"Pellegrini C, Broccoli A, Pulsoni A, Rigacci L, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Santoro A, Hoaus S, Rigolin GM, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Ronconi F, Gritti G, Vallisa D, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Bianchi MP, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Carella AM, Stefoni V, Argnani L, Zinzani PL (2017) Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed\/refractory Hodgkin's lymphoma. Oncotarget 8(53):91703\u201391710. https:\/\/doi.org\/10.18632\/oncotarget.18114","DOI":"10.18632\/oncotarget.18114"},{"key":"5100_CR13","doi-asserted-by":"publisher","unstructured":"Pavone V, Mele A, Carlino D, et al. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma na\u00efve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP). Ann Hematol. 2018;97(10). https:\/\/doi.org\/10.1007\/s00277-018-3379-5","DOI":"10.1007\/s00277-018-3379-5"},{"issue":"14","key":"5100_CR14","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A et al (2018) Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 36(14):1428\u20131439. https:\/\/doi.org\/10.1200\/JCO.2017.76.0793","journal-title":"J Clin Oncol"},{"issue":"19","key":"5100_CR15","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA et al (2017) Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol 35(19):2125\u20132132. https:\/\/doi.org\/10.1200\/JCO.2016.72.1316","journal-title":"J Clin Oncol"},{"issue":"9","key":"5100_CR16","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M et al (2016) Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17(9):1283\u20131294. https:\/\/doi.org\/10.1016\/S1470-2045(16)30167-X","journal-title":"Lancet Oncol"},{"issue":"27","key":"5100_CR17","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification. J Clin Oncol 32(27):3059\u20133067. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"issue":"21","key":"5100_CR18","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L et al (2016) Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128(21):2489\u20132496. https:\/\/doi.org\/10.1182\/blood-2016-05-718528","journal-title":"Blood"},{"issue":"4","key":"5100_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I et al (2015) PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372(4):311\u2013319. https:\/\/doi.org\/10.1056\/NEJMoa1411087","journal-title":"N Engl J Med"},{"issue":"14","key":"5100_CR20","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A et al (2018) Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II Checkmate 205 trial. J Clin Oncol 36(14):1428\u20131439. https:\/\/doi.org\/10.1200\/JCO.2017.76.0793","journal-title":"J Clin Oncol"},{"issue":"31","key":"5100_CR21","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","volume":"34","author":"P Armand","year":"2016","unstructured":"Armand P, Shipp MA, Ribrag V et al (2016) Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 34(31):3733\u20133739. https:\/\/doi.org\/10.1200\/JCO.2016.67.3467","journal-title":"J Clin Oncol"},{"issue":"7","key":"5100_CR22","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1634\/theoncologist.2018-0538","volume":"24","author":"SM Bair","year":"2019","unstructured":"Bair SM, Strelec LE, Feldman TA et al (2019) Outcomes and toxicities of programmed death-1 (PD-1) inhibitors in Hodgkin lymphoma patients in the United States: a real-world, multicenter retrospective analysis. Oncologist 24(7):955\u2013962. https:\/\/doi.org\/10.1634\/theoncologist.2018-0538","journal-title":"Oncologist"},{"issue":"11","key":"5100_CR23","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1007\/s00277-020-04077-4","volume":"99","author":"H Bekoz","year":"2020","unstructured":"Bekoz H, Ozbalak M, Karadurmus N et al (2020) Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Ann Hematol 99(11):2565\u20132576. https:\/\/doi.org\/10.1007\/s00277-020-04077-4","journal-title":"Ann Hematol"},{"issue":"2","key":"5100_CR24","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bjh.18231","volume":"198","author":"J Momotow","year":"2022","unstructured":"Momotow J, B\u00fchnen I, Trautmann-Grill K et al (2022) Outcomes of anti-programmed death 1 treatment for relapsed\/refractory Hodgkin lymphoma: a German Hodgkin Study Group multicentre real-world analysis. Br J Haematol 198(2):401\u2013404. https:\/\/doi.org\/10.1111\/bjh.18231","journal-title":"Br J Haematol"},{"key":"5100_CR25","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2147\/TCRM.S308194","volume":"17","author":"F Grimaud","year":"2021","unstructured":"Grimaud F, Penaranda G, Stavris C et al (2021) Adverse events induced by pd-1\/pd-l1 inhibitors: a real-world single-centre experience with a management-based approach. Ther Clin Risk Manag 17:669\u2013677. https:\/\/doi.org\/10.2147\/TCRM.S308194","journal-title":"Ther Clin Risk Manag"},{"key":"5100_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2019.04.006","volume":"115","author":"G Manson","year":"2019","unstructured":"Manson G, Mear JB, Herbaux C et al (2019) Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. Eur J Cancer 115:47\u201356. https:\/\/doi.org\/10.1016\/j.ejca.2019.04.006","journal-title":"Eur J Cancer"},{"issue":"1","key":"5100_CR27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1756-8722-7-24","volume":"7","author":"NL Bartlett","year":"2014","unstructured":"Bartlett NL, Chen R, Fanale MA et al (2014) Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol 7(1):24. https:\/\/doi.org\/10.1186\/1756-8722-7-24","journal-title":"J Hematol Oncol"},{"issue":"14","key":"5100_CR28","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1182\/blood.2019000324","volume":"134","author":"R Chen","year":"2019","unstructured":"Chen R, Zinzani PL, Lee HJ et al (2019) Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood 134(14):1144\u20131153. https:\/\/doi.org\/10.1182\/blood.2019000324","journal-title":"Blood"},{"issue":"4","key":"5100_CR29","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s00259-020-05015-2","volume":"48","author":"G Manson","year":"2021","unstructured":"Manson G, Brice P, Herbaux C et al (2021) Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 48(4):1144\u20131153. https:\/\/doi.org\/10.1007\/s00259-020-05015-2","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"5100_CR30","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","volume":"6","author":"PJ Br\u00f6ckelmann","year":"2020","unstructured":"Br\u00f6ckelmann PJ, Goergen H, Keller U et al (2020) Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma. JAMA Oncol 6(6):872. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0750","journal-title":"JAMA Oncol"},{"issue":"11","key":"5100_CR31","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30275-1","volume":"7","author":"BD Cheson","year":"2020","unstructured":"Cheson BD, Bartlett NL, LaPlant B et al (2020) Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Lancet Haematol 7(11):e808\u2013e815. https:\/\/doi.org\/10.1016\/S2352-3026(20)30275-1","journal-title":"Lancet Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05100-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05100-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05100-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T09:11:04Z","timestamp":1675156264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05100-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["5100"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05100-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,16]]},"assertion":[{"value":"21 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}